新闻稿
生理学是全球最先进的预防健康和诊断诊所，今天，宣布用Caristo诊断公司的CaRi-Heart 技术完成了首次美国研究，评估无症状、低风险个人的AI动力冠状炎检测。 研究显示，冠状炎症在无已知心脏病的无症状成年人中非常普遍，并且没有通过标准的血液检测和其他传统的心血管风险因素来发现。
该研究可供符合临床条件的Biograph Black 级成员使用，将Biograph的高级诊断(包括高分辨率的冠状计算成像成像和心电图剖析)与Caristo的CaRi-Heart和CaRi-Plaque技术结合起来。 这一合作方法使研究人员能够利用人工智能辅助的CaRi-Heart技术评估冠状炎的流行情况，以确定本来通过传统筛查可能出现低风险的个人的心血管风险。
研究发现，冠状炎症在无症状、低风险的成年人中是常见的(42.9%)，而且经常发生，没有任何斑点积聚或阻塞。 具体来说，42.9%的参与者表现出较高的炎症，17.9%的参与者在至少一个主要的心脏动脉中表现出非常高的炎症。 结果还表明，标准评估可能存在局限性：约47%的参与者没有可探测的冠状板显示冠状血管炎高发。 通过评估冠状炎症以及传统的图象评估斑块负担和快感，我们得到了更完整的心血管风险。
重要的是，常规的血液工作和临床工具 — — 包括胆固醇标记(ApoB，非HDL-C)，血糖(HbA1c)，系统性炎症(hs-CRP)，以及广泛使用的心血管风险计算器(AHA PREVENT-ASCVD) — — 与冠状炎症的存在没有任何关联性，未能识别哪些患者引发动脉炎。 这些结果强化了Biograph的核心哲学：孤立的血液工作和孤立的衡量标准并不能说明整个故事。 通过直接分析围绕冠状动脉的组织生物学，这种非侵入性AI技术在不可逆性心脏病发作前的几年发现了潜在的心血管风险。
"冠心病，无论是板状积聚还是动脉性激素化，都可能是船只壁内主动煽动过程的后期后果。 我们的调查结果令人惊讶的是，42%以上的无症状的、传统的低风险的成年人增加了冠状炎症，许多炎症程度最高的人对CT进行了完全正常的冠状解剖。 关键是，没有常规的血液生物标记、脂质测量或临床风险分数能够识别出这些有发炎冠状动脉的人。 这项研究表明，我们可能正在确定疾病的一个上游阶段和主动干预的窗口。 需要更多的研究来验证这一发现，并确定针对冠心血管炎的护理的预测价值和好处".
就Biograph而言，这项研究的完成反映了其更广泛的使命，即通过综合诊断、临床解释和早期对长期健康风险的洞察，推进主动、个性化的保健。 为了审查临床研究手稿，读者可以在此查阅已出版的预印本。
*CaRi-Heart 已获得美国食品药品管理局(FDA)De Novo营销授权，是将日常冠状CT血管炎(CCTA)量化的第一个也是唯一的解决方案。 Cari-Plaque 已经获得美国FDA许可，可以进行AI辅助的冠状标牌和快感分析，通过评价定量标牌来补充Cari-Heart.
生物图
记者询问，请联系@biograph.com
生理学的使命是推动在人类健康和寿命方面取得有意义的进展。 我们不只是在帮助你活得更长我们每年的精力都集中在做最好的因为你的生活有多美好和你活多久一样重要以人类为中心的设计为重点，我们创建了一个无与伦比的临床设施来挑战行业规范。 我们承诺在我们每个成员的整个生平历程中给予他们特殊服务。 我们不断将新的研究纳入我们的方法，以保持医学的前沿。
本文由 AI图鉴自动抓取并翻译，版权归原作者所有；如需查看原文请点下方链接。
Press Release
Biograph, the world’s most advanced preventive health and diagnostics clinic, today announced the completion of its first U.S. study using Caristo Diagnostics’ CaRi-Heart® technology evaluating AI-powered coronary inflammation detection in asymptomatic, low-risk individuals. The research revealed that coronary inflammation is widespread among asymptomatic adults without known heart disease – and is undetected by standard blood tests and other traditional cardiovascular risk factors.
The study, available to clinically eligible Biograph Black tier members, combined Biograph’s advanced diagnostics – including high-resolution coronary computed tomography angiography (CCTA) imaging and cardiometabolic profiling – with Caristo’s CaRi-Heart and CaRi-Plaque® technologies*. This collaborative methodology enabled researchers to assess the prevalence of coronary inflammation using the AI-enabled CaRi-Heart technology to determine cardiovascular risk in individuals who may otherwise appear low risk through traditional screening.
The study found that coronary inflammation is common (42.9%) in asymptomatic, low-risk adults and frequently occurs without any plaque buildup or blockage. Specifically, 42.9% of participants exhibited elevated inflammation with 17.9% of participants exhibiting very high inflammation in at least one major heart artery. The results also suggest a potential limitation in standard assessment: About 47% of participants with no detectable coronary plaque exhibited elevated coronary perivascular inflammation. By evaluating coronary inflammation alongside traditional imaging assessment of plaque burden and stenosis, we get a more complete picture of cardiovascular risk..
Importantly, routine bloodwork and clinical tools – including cholesterol markers (ApoB, non-HDL-C), blood sugar (HbA1c), systemic inflammation (hs-CRP), and a widely used cardiovascular risk calculator (AHA PREVENT-ASCVD) – showed no correlation with the presence of coronary inflammation and failed to identify which patients had inflamed arteries. These results reinforce Biograph’s core philosophy: standalone bloodwork and isolated metrics do not tell the full story. By directly analyzing the biology of the tissue surrounding the coronary arteries, this non-invasive AI technology uncovers potential cardiovascular risk years before the onset of irreversible heart disease.
"Coronary heart disease, whether plaque accumulation or arterial stenosis, is likely a late consequence of an active inflammatory process in the vessel wall. What is striking about our findings is that more than 42% of asymptomatic, conventionally low-risk adults had elevated coronary inflammation, and many individuals with the highest inflammatory levels had completely normal coronary anatomy on CT. Crucially, no routine blood biomarker, lipid metric, or clinical risk score could identify these individuals with inflamed coronary arteries. This study suggests we may be identifying an upstream phase of disease and a window for proactive intervention. More research is needed to validate this finding and establish the prognostic value and benefit of care directed at coronary perivascular inflammation."
For Biograph, the completion of this study reflects its broader mission to advance proactive, personalized healthcare through comprehensive diagnostics, clinical interpretation, and earlier insight into long-term health risks. To review the clinical study manuscript, readers can access the published preprint here.
*CaRi-Heart® has received U.S. Food and Drug Administration (FDA) De Novo marketing authorization and is the first and only solution to quantify coronary inflammation from routine coronary CT angiography (CCTA). CaRi-Plaque® has received U.S. FDA clearance for AI-assisted coronary plaque and stenosis analysis, complementing CaRi-Heart by evaluating quantitative plaque.
Biograph
For press inquiries, get in touch at press@biograph.com
Biograph is on a mission to drive meaningful advances in human healthspan and lifespan. We're not simply focused on helping you live longer. We're focused on making every year the best it can be. Because how well you live is as important as how long you live. With an emphasis on human centered design, we've created an unparalleled clinical facility to defy industry norms. We are committed to giving each of our Members exceptional service throughout their Biograph journey. We continuously incorporate new research into our method to remain on the cutting edge of medicine.
Auto-fetched and translated by AI Atlas. All rights belong to the original author.